GERN: Geron Corp.
About
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.
Current Value
$3.761 Year Return
Current Value
$3.761 Year Return
Key Details
Market Cap
$2.29B
P/E Ratio
-11.77
1Y Stock Return
97.40%
1Y Revenue Growth
9199.68%
Dividend Yield
0.00%
Price to Book
7.8
Strategies that include GERN
Stock's related to GERN
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CDLX | 52.46% | $178.39M | -54.00% | 0.00% |
| TG | 49.36% | $244.31M | +47.82% | 0.00% |
| CSGP | 37.36% | $29.55B | -13.45% | 0.00% |
| AVD | 35.11% | $182.80M | -32.45% | 1.42% |
| LAW | 34.05% | $325.90M | -3.37% | 0.00% |
| VERI | 33.56% | $111.67M | +35.81% | 0.00% |
| JRVR | 31.45% | $168.34M | -52.25% | 4.52% |
| AXSM | 30.42% | $4.63B | +61.30% | 0.00% |
| DESP | 28.66% | $1.16B | +111.97% | 0.00% |
| MSDL | 28.61% | $1.83B | +0.66% | 7.26% |
| FORR | 28.54% | $313.81M | -33.68% | 0.00% |
| HEAR | 28.48% | $300.79M | +44.04% | 0.00% |
| SEER | 28.15% | $134.44M | +40.74% | 0.00% |
| XNCR | 28.10% | $1.65B | +27.73% | 0.00% |
| JYNT | 27.72% | $164.07M | +24.57% | 0.00% |
| MGTX | 27.56% | $467.36M | +9.12% | 0.00% |
| KROS | 26.82% | $2.17B | +73.87% | 0.00% |
| FBIO | 26.54% | $43.83M | -27.73% | 0.00% |
| MDGL | 26.45% | $6.85B | +66.72% | 0.00% |
| NTLA | 25.99% | $1.44B | -50.35% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DXCM | <0.01% | $29.25B | -31.28% | 0.00% |
| SAP | -0.05% | $268.13B | +52.92% | 1.02% |
| HUM | -0.09% | $33.45B | -45.22% | 1.25% |
| IBKR | -0.13% | $20.20B | +131.83% | 0.37% |
| OLLI | 0.14% | $5.48B | +15.97% | 0.00% |
| PUBM | 0.15% | $739.82M | -2.82% | 0.00% |
| BACK | -0.15% | $1.76M | -32.90% | 0.00% |
| NTNX | 0.15% | $18.33B | +70.72% | 0.00% |
| BKNG | -0.16% | $164.72B | +58.25% | 0.53% |
| CRWD | -0.16% | $86.61B | +69.05% | 0.00% |
| TCTM | 0.16% | $8.10M | -42.99% | 0.00% |
| VST | -0.16% | $52.69B | +349.00% | 0.56% |
| CNA | -0.19% | $13.16B | +23.03% | 3.61% |
| WRB | 0.22% | $22.94B | +29.98% | 0.69% |
| LPLA | 0.22% | $23.55B | +38.13% | 0.38% |
| DUOL | 0.23% | $14.17B | +49.85% | 0.00% |
| ATHM | 0.23% | $3.30B | -0.04% | 4.18% |
| HUBS | 0.24% | $35.23B | +44.73% | 0.00% |
| IBM | -0.24% | $194.41B | +36.61% | 3.16% |
| SPOT | 0.24% | $90.80B | +159.59% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ADBE | -30.40% | $219.93B | -18.23% | 0.00% |
| JBL | -25.49% | $14.39B | -2.61% | 0.25% |
| GRPN | -24.58% | $353.14M | -10.75% | 0.00% |
| CMBT | -18.23% | $2.46B | -29.63% | 13.05% |
| ETON | -15.78% | $271.28M | +195.77% | 0.00% |
| AVAL | -15.60% | $791.37M | -4.11% | 7.14% |
| STG | -15.60% | $35.67M | +7.92% | 0.00% |
| CME | -12.38% | $82.76B | +9.21% | 1.98% |
| CIG.C | -12.27% | $2.48B | -3.55% | 0.00% |
| GSK | -11.71% | $68.24B | -5.43% | 4.71% |
| EVCM | -10.25% | $2.06B | +33.33% | 0.00% |
| OPRT | -9.61% | $112.95M | +40.81% | 0.00% |
| ULTA | -9.44% | $16.12B | -15.50% | 0.00% |
| SMAR | -9.39% | $7.79B | +36.62% | 0.00% |
| SMC | -9.37% | $383.35M | +97.26% | 0.00% |
| ABT | -8.42% | $203.16B | +14.93% | 1.88% |
| KSPI | -8.15% | $20.86B | +18.06% | 3.37% |
| QSR | -8.09% | $22.48B | -1.07% | 3.30% |
| MMC | -7.88% | $108.41B | +10.89% | 1.37% |
| CODX | -7.70% | $34.16M | -25.17% | 0.00% |
ETF's related to GERN
News
Yahoo
FOSTER CITY, Calif., November 11, 2024--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, effective today, November 11, 2024. In this role, Dr. Eid will lead our Research and Development organization comprised of medical, clinical, and safety/pharmacovigilance teams and be responsible for driving inn
Yahoo
FOSTER CITY, Calif., November 11, 2024--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to participate in a fireside chat at the Stifel 2024 Healthcare Conference, in New York City, on Monday, November 18th, 2024, at 1:50pm ET.
Yahoo
Geron Corporation ( NASDAQ:GERN ) investors will be delighted, with the company turning in some strong numbers with its...
Yahoo
Geron ( NASDAQ:GERN ) Third Quarter 2024 Results Key Financial Results Revenue: US$28.3m (up by US$28.1m from 3Q 2023...
Yahoo
Geron Corp (GERN) reports impressive Rytelo revenue and secures $250 million through innovative financing, despite facing competitive challenges.
Yahoo
The latest announcement is out from Geron ( (GERN) ). Geron Corporation has secured $250 million in funding through a loan agreement with Pharmakon Advisors and a synthetic royalty deal with Royalty Pharma, strengthening its financial position. This includes a $125 million loan tranche and $125 million from Royalty Pharma for tiered royalties on U.S. sales of RYTELO. Geron’s strong Q3 performance, with $28.2 million in RYTELO sales, underscores its commercial potential, supported by the company’
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.